Radium
As of the edition of 20 October 2026, Radium is a small molecule: marketed, first approved in 2018 (CH).
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2018
- Kind
- Small molecule
- First approved
- 13 November 2018 (CH)
- Approvals on record
- 1 in 1 region
- Holder of the most recent approval
- Boiron
- Registered trials
- 22, 2 stopped early
- Disease areas
- Cancer; Urinary and reproductive; Pregnancy and women's health
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 5 | 4 | 0 | 0 |
| Phase 1 | 4 | 2 | 1 | 1 |
| Phase 2 | 10 | 6 | 4 | 0 |
| Phase 3 | 2 | 0 | 1 | 1 |
| Phase 4 | 1 | 0 | 0 | 0 |
| All trials | 22 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Boiron | Applicant | 2018 to now |